Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients.
A blood test–based risk score helps predict which lung cancer patients will develop brain spread, improving decisions about preventive brain radiation.
This study develops a liquid biopsy-based genomic risk score for predicting neurologic death in NSCLC patients, leveraging cell-free DNA profiling. The prognostic tool may improve treatment decision-making for patients at risk of CNS progression.
What the study was
- Study design
- Retrospective cohort study with predictive modeling
- Population
- NSCLC patients (brain metastases context)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Journal of Neuro-Oncology
Why it surfaced
Novel liquid biopsy risk score for neurologic death in NSCLC; addresses an important clinical question about CNS-directed treatment selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.